tiprankstipranks
Dianthus announces FDA clearance to initiate Phase 2 trial of DNTH103
PremiumThe FlyDianthus announces FDA clearance to initiate Phase 2 trial of DNTH103
1M ago
Dianthus initiated with an Outperform at LifeSci Capital
PremiumThe Fly
Dianthus initiated with an Outperform at LifeSci Capital
1M ago
Dianthus Therapeutics Presents Future Outlook at Conference
PremiumCompany Announcements
Dianthus Therapeutics Presents Future Outlook at Conference
2M ago
Dianthus price target raised to $38 from $33 at Wedbush
PremiumThe FlyDianthus price target raised to $38 from $33 at Wedbush
2M ago
Dianthus reports Q1 EPS (54c), consensus (44c)
PremiumThe Fly
Dianthus reports Q1 EPS (54c), consensus (44c)
2M ago
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results
PremiumPress Releases
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results
2M ago
Dianthus announces oral presentation for DNTH103
PremiumThe FlyDianthus announces oral presentation for DNTH103
3M ago
Drugmakers look to alternative suppliers after draft U.S. legislation, FT says
PremiumThe Fly
Drugmakers look to alternative suppliers after draft U.S. legislation, FT says
3M ago
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PremiumPress Releases
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100